The Galien Foundation Announces 2024 Prix Galien USA Nominees for "Best Biotechnology Product," "Best Pharmaceutical Product" and "Best Product for Rare/Orphan Diseases"
"We are thrilled to recognize the outstanding achievements of those who have devoted their expertise to advancing healthcare and improving lives, globally," said
The 2024
To qualify, each candidate must be
Best Biotechnology Product (Nominees)
Amgen and AstraZeneca |
TEZSPIRE® |
Arcutis Biotherapeutics, Inc. |
ZORYVE® |
argenx |
VYVGART® |
AstraZeneca and Sanofi |
Beyfortus® |
BeiGene |
Brukinsa® |
Daiichi Sankyo & AstraZeneca |
ENHERTU® |
Genmab and AbbVie |
EPKINLY® |
GSK |
AREXVY |
|
XACDURO® |
Ipsen |
Bylvay® |
Jazz Pharmaceuticals |
Rylaze® |
Johnson & Johnson |
TALVEY™ |
Johnson & Johnson |
TECVAYLI™ |
Johnson & Johnson and |
CARVYKTI® |
Merck & Co Inc. |
CAPVAXIVE™ |
MGI Tech |
DNBSEQ-T20 |
|
PREVNAR 20® |
|
ABRYSVO® |
Regeneron and Sanofi |
Dupixent® |
VBI Vaccines Inc. |
PreHevbrio™ |
XVIVO Perfusion |
XPS with STEEN Solution |
Best Pharmaceutical Product (Nominees)
AbbVie |
ELAHERE® |
|
LYBALVI® |
Ardelyx, Inc. |
XPHOZAH® |
Aurinia Pharmaceuticals Inc. |
LUPKYNIS® |
Biogen Inc. and Sage Therapeutics |
ZURZUVAE® |
Eisai and Biogen Inc. |
LEQEMBI® |
Eli Lilly and Company |
Kisunla™ |
|
Ocrevus® |
|
PHESGO® |
|
VABYSMO™ |
Gilead Sciences |
Sunlenca® |
Glaukos Corporation |
iDose® TR |
Incyte |
Opzelura® |
|
JORNAY PM ® |
Johnson & Johnson |
RYBREVANT® |
Merck & Co. Inc. |
WINREVAIR™ |
Mirum Pharmaceuticals, Inc. |
LIVMARLI® (maralixibat) oral solution |
Novartis |
PLUVICTO® |
|
CIBINQO® |
|
PAXLOVID™ |
Phathom Pharmaceuticals |
VOQUEZNA® (vonoprazan) |
Sanofi |
Tzield® |
|
TIBSOVO® |
|
Myfembree® |
|
Apretude (cabotegravir extended-release |
Best Product for Rare/Orphan Diseases (Nominees)
AstraZeneca and Ionis Pharmaceuticals |
WAINUA™ |
Biogen Inc. |
SKYCLARYS ® |
Biogen Inc. and Ionis Pharmaceuticals |
QALSODY® |
|
KIMMTRAK® |
Marinus Pharmaceuticals, Inc. |
ZTALMY® |
Regeneron |
Evkeeza® |
Sanofi |
Xenpozyme® |
SpringWorks Therapeutics |
OGSIVEO® |
"Each year, we have the honor of convening in
Michael ROSENBLATT
M.D., Galien Forum Co-Chair, Former Dean of
Linda BUCK
Ph.D.,
Sue DESMOND-HELLMANN
M.D., M.P.H., Former Chief Executive Officer,
Laurie GLIMCHER
M.D., President and CEO,
Mary-Claire KING
Ph.D., American Cancer Society Professor of Genome Sciences and Medical Genetics,
Robert S. LANGER
M.D., David H. Koch Institute Professor,
Cato T. LAURENCIN
M.D., Ph.D., Chief Executive Officer,
Steven J. LESTER
M.D., Chief Medical Officer, Mayo Clinic-ASU MedTech Accelerator
Stanley B. PRUSINER
M.D., Nobel Laureate, Professor of Neurology, Director,
Phillip A. SHARP
Ph.D.,
Marc TESSIER-LAVIGNE
Ph.D., President Emeritus and Professor,
About
The Foundation oversees and directs activities in the US for the Prix Galien, an international awards program dedicated to progress through innovative medicines development, with chapters in 14 countries,
For more information, visit www.galienfoundation.org.
Follow the Foundation on social media:
https://www.facebook.com/GalienFoundation/
https://twitter.com/GalienFdn
https://www.linkedin.com/company/the-galien-foundation/
Media Contact:
Kara.Bradley@finnpartners.com
646-213-7243
View original content to download multimedia:https://www.prnewswire.com/news-releases/the-galien-foundation-announces-2024-prix-galien-usa-nominees-for-best-biotechnology-product-best-pharmaceutical-product-and-best-product-for-rareorphan-diseases-302218512.html
SOURCE